Nanjing Delova

Nanjing Delova is a clinical-stage biotechnology company based in China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages a proprietary structure-based drug design (SBDD) platform to target high-value oncogenic drivers and immunological pathways. Its pipeline includes several potent inhibitors targeting FGFR, RET, and BTK, with lead programs currently undergoing clinical evaluation for various solid tumors and hematological malignancies. Delova aims to address unmet medical needs through precision medicine and has secured significant backing from prominent venture capital firms including Lilly Asia Ventures and Qiming Venture Partners.